HomeCompareDSKYF vs PLD

DSKYF vs PLD: Dividend Comparison 2026

DSKYF yields 2.50% · PLD yields 3.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DSKYF wins by $169.68M in total portfolio value· pulled ahead in Year 2
10 years
DSKYF
DSKYF
● Live price
2.50%
Share price
$18.42
Annual div
$0.46
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$175.59M
Annual income
$163,081,726.45
Full DSKYF calculator →
PLD
PLD
● Live price
3.10%
Share price
$132.18
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.91M
Annual income
$4,750,725.19
Full PLD calculator →

Portfolio growth — DSKYF vs PLD

📍 DSKYF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDSKYFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DSKYF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DSKYF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DSKYF
Annual income on $10K today (after 15% tax)
$212.91/yr
After 10yr DRIP, annual income (after tax)
$138,619,467.48/yr
PLD
Annual income on $10K today (after 15% tax)
$263.66/yr
After 10yr DRIP, annual income (after tax)
$4,038,116.41/yr
At 15% tax rate, DSKYF beats the other by $134,581,351.07/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DSKYF + PLD for your $10,000?

DSKYF: 50%PLD: 50%
100% PLD50/50100% DSKYF
Portfolio after 10yr
$90.75M
Annual income
$83,916,225.81/yr
Blended yield
92.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

DSKYF
No analyst data
Altman Z
3.4
Piotroski
6/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+2.9% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DSKYF buys
0
PLD buys
0
No recent congressional trades found for DSKYF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDSKYFPLD
Forward yield2.50%3.10%
Annual dividend / share$0.46$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%74.4%
Portfolio after 10y$175.59M$5.91M
Annual income after 10y$163,081,726.45$4,750,725.19
Total dividends collected$174.63M$5.78M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: DSKYF vs PLD ($10,000, DRIP)

YearDSKYF PortfolioDSKYF Income/yrPLD PortfolioPLD Income/yrGap
1$11,201$500.97$11,241$540.96$40.00PLD
2← crossover$13,034$1,048.84$13,019$991.13+$15.00DSKYF
3$16,228$2,281.26$15,801$1,870.97+$427.00DSKYF
4$22,672$5,308.83$20,609$3,701.21+$2.1KDSKYF
5$38,123$13,863.99$29,919$7,867.97+$8.2KDSKYF
6$84,366$43,574.29$50,631$18,617.74+$33.7KDSKYF
7$270,513$180,241.39$105,528$51,352.20+$165.0KDSKYF
8$1,369,690$1,080,240.94$287,364$174,449.42+$1.08MDSKYF
9$11,689,092$10,223,523.95$1,081,760$774,280.77+$10.61MDSKYF
10$175,589,055$163,081,726.45$5,908,209$4,750,725.19+$169.68MDSKYF

DSKYF vs PLD: Complete Analysis 2026

DSKYFStock

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Full DSKYF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this DSKYF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DSKYF vs SCHDDSKYF vs JEPIDSKYF vs ODSKYF vs KODSKYF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.